Logo-bi
Review

1. Dysregulated pH in Tumor Microenvironment Checkmates Cancer Therapy
Jaleh Barar ORCID, Yadollah Omidi* ORCID
Bioimpacts. 2013;3(4): 149-162. doi: 10.5681/bi.2013.036
PMCID: PMC3892734     PMID: 24455478     Scopus ID: 84893354269    
Article
PDF
XML
Cited By:
170
63
0
Review

2. Targeting tumor microenvironment: crossing tumor interstitial fluid by multifunctional nanomedicines
Yadollah Omidi ORCID, Jaleh Barar* ORCID
Bioimpacts. 2014;4(2): 55-67. doi: 10.5681/bi.2014.021
PMCID: PMC4097973     PMID: 25035848     Scopus ID: 84905435584    
Article
PDF
XML
Cited By:
121
40
0
Editorial

3. Targeting Tumor Microenvironment: The Key Role of Immune System
Jaleh Barar* ORCID
Bioimpacts. 2012;2(1): 1-3. doi: 10.5681/bi.2012.001
PMCID: PMC3648920     PMID: 23678436     Scopus ID: 84876816540    
Article
PDF
XML
Cited By:
19
9
0
Review

4. Molecular machineries of pH dysregulation in tumor microenvironment: potential targets for cancer therapy
Mohammad Reza Asgharzadeh, Jaleh Barar ORCID, Mohammad M. Pourseif, Morteza Eskandani, Mojtaba Jafari Niya, Mohammad Reza Mashayekhi, Yadollah Omidi* ORCID
Bioimpacts. 2017;7(2): 115-133. doi: 10.15171/bi.2017.15
PMCID: PMC5524986     PMID: 28752076     Scopus ID: 85027460324    
Article
PDF
Full Text
XML
Cited By:
96
39
95
Editorial

5. Renewed interests in carbonic anhydrase IX in relevance to breast cancer treatment
Mitra Dolatkhah, Yadollah Omidi* ORCID
Bioimpacts. 2019;9(4): 195-197. doi: 10.15171/bi.2019.24
PMCID: PMC6879713     PMID: 31799155     Scopus ID: 85077126191    
Article
PDF
Full Text
XML
Cited By:
9
2
9
Dr. Yadollah Omidi (Pharm.D., Ph.D.) is a Professor of Pharmaceutical Sciences at TUOMS Faculty of Pharmacy, working on advanced multifunctional nanobiosystems. He has worked at Cardiff University and University of Pennsylvania. He has published over 210 papers and 18 book chapters, supervised and mentored over 100 graduate/postgraduate students/researchers.
Review

6. Recent advances in cancer immunotherapy: Modulation of tumor microenvironment by Toll-like receptor ligands
Leila Rostamizadeh ORCID, Ommoleila Molavi* ORCID, Mohsen Rashid, Fatemeh Ramazani, Behzad Baradaran, Afsaneh Lavasanaifar, Raymond Lai
BioImpacts. 2022;12(3): 261-290. doi: 10.34172/bi.2022.23896
PMCID: PMC9124882     PMID: 35677663     Scopus ID: 85132074584    
Article
PDF
Full Text
XML
Cited By:
16
5
4
In this paper, we will review the application of the four most widely studied TLR agonists including agonists of TLR3, 4, 7, and 9 in cancer immunotherapy.
Original Article

7. Modulating the tumor microenvironment improves antitumor effect of anti-PD-L1 mAb in breast cancer
Xiuying Li* ORCID, Xianqin Luo, Shunqin Hu
Bioimpacts. 2023;13(2): 89-96. doi: 10.34172/bi.2023.24166
PMCID: PMC10182444     PMID: 37193073     Scopus ID: 85152093865    
Article
PDF
Full Text
XML
Cited By:
1
0
0
Our results indicated that losartan can modulate the tumor microenvironment, and improve the efficacy of anti-PD-L1 mAb.
Original Article

8. Studying luminal A and B subtypes of breast cancer under paracrine secretion of fibro- blasts
Nazila Jalilzadeh ORCID, Neda Barzgar Barough, Mehrdad Karami, Amir Baghbanzadeh, Kobra Velaei* ORCID
Bioimpacts. 2024;14(3): 27591. doi: 10.34172/bi.2023.27591
PMCID: PMC11199934     PMID: 38938757     Scopus ID: 85194774105    
Article
PDF
XML
Cited By:
0
0
0

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate: 24% 
Publication fee: Free of charge